AMENDMENTS TO THE CLAIMS

1. (Canceled)

2. (Currently amended) A method for treating a patient having lung cancer ~~a neoplasm~~, said method comprising administering to said patient:

a) a first compound having the formula (I):



(I) ,

or a pharmaceutically acceptable salt thereof,

wherein R^2 is selected from the group consisting of: CF_3, halo, OCH_3, $COCH_3$, CN, OCF_3, $COCH_2CH_3$, $CO(CH_2)_2CH_3$, and SCH_2CH_3;

R^9 has the formula:



,

wherein n is 0 or 1, each of R^{32}, R^{33}, and R^{34} is, independently, H or substituted or unsubstituted C_{1-6} alkyl, and Z is $NR^{35}R^{36}$ or OR^{37}, wherein each of R^{35} and R^{36} is, independently, H, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted alkaryl, substituted or unsubstituted alkheteroaryl, and R^{37} is H, C_{1-6} alkyl, or C_{1-7} acyl,

wherein any of R^{33}, R^{34}, R^{35}, and R^{36} can be optionally taken together with intervening carbon or non-vicinal O, S, or N atoms to form one or more five- to seven-membered rings, substituted with one or more hydrogens, substituted or unsubstituted C_{1-6} alkyl groups, C_{6-12} aryl groups, alkoxy groups, halogen groups, substituted or unsubstituted alkaryl groups, or substituted or unsubstituted alkheteroaryl groups;

each of R^1, R^3, R^4, R^5, R^6, R^7, and R^8 is independently H, OH, F, OCF_3, or OCH_3; and W is selected from the group consisting of:



; and

b) a second compound of formula (II):, wherein said compound of formula (II) is



(II),

or a pharmaceutically acceptable salt thereof,

wherein A is



,

each of X and Y is, independently, O or NH,

p is an integer between 2 and 6, inclusive,

each of m and n is, independently, an integer between 0 and 2, inclusive, wherein the sum of m and n is greater than 0,

each of R^{10} and R^{11} is, independently, selected from the group represented by



,

wherein R^{21} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or , R^{22} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_6-C_{18} aryloxy C_1-C_6 alkyl, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, carbo(C_1-C_6 alkoxy), carbo(C_6-C_{18} aryl-C_1-C_6 alkoxy), carbo(C_6-C_{18} aryloxy), or C_6-C_{18} aryl, and R^{20} is H, OH, or oxy(C_1-C_6 alkyl), or R^{20} and R^{21} together represent



wherein each of R^{23}, R^{24}, and R^{25} is, independently, H, C_1-C_6 alkyl, halogen, or trifluoromethyl, each of R^{26}, R^{27}, R^{28}, and R^{29} are, independently, H or C_1-C_6 alkyl, and R^{30} is H, halogen, trifluoromethyl, OCF_3, NO_2, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl,

each of R^{12} and R^{13} is, independently, H, Cl, Br, OH, OCH_3, OCF_3, NO_2, and NH_2, or R^{12} and R^{13} together form a single bond;

or A is



,

each of X and Y is, independently, O or NH,

p is an integer between 2 and 6, inclusive,

each of m and n is 0, and

each of R^{10} and R^{11} is, independently, selected from the group represented by



,

wherein R^{21} is C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl, R^{22} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, carbo(C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryl C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryloxy), or C_6-C_{18} aryl, and R^{20} is H, OH, or C_1-C_6 alkyloxy, or R^{20} and R^{21} together represent



,

wherein each of R^{23}, R^{24}, and R^{25} is, independently, H, C_1-C_6 alkyl, halogen, or trifluoromethyl, each of R^{26}, R^{27}, and R^{28} is, independently, H or C_1-C_6 alkyl, and R^{29} is C_1-C_6 alkyl, C_1-C_6 alkyloxy, or trifluoromethyl;

or A is



each of X and Y is, independently, O, NR^{19}, or S,

each of R^{14} and R^{19} is, independently, H or C_1-C_6 alkyl,

each of R^{15}, R^{16}, R^{17}, and R^{18} is, independently, H, C_1-C_6 alkyl, halogen, C_1-C_6 alkyloxy, C_6-C_{18} aryloxy, or C_6-C_{18} aryl C_1-C_6 alkyloxy,

R^{31} is C_1-C_6 alkyl,

p is an integer between 2 and 6, inclusive,

each of m and n is, independently, an integer between 0 and 2, inclusive,

each of R^{10} and R^{11} is, independently, selected from the group represented by



wherein R^{21} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl, R^{22} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_6-C_{18} aryloxy C_1-C_6 alkyl, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, carbo(C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryl C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryloxy), or C_6-C_{18} aryl, and R^{20} is H, OH, or C_1-C_6 alkyloxy, or R^{20} and R^{21} together represent



wherein each of R^{23}, R^{24}, and R^{25} is, independently, H, C_1-C_6 alkyl, halogen, or trifluoromethyl, each of R^{26}, R^{27}, R^{28}, and R^{29} are, independently, H or C_1-C_6 alkyl, and R^{30} is H, halogen, trifluoromethyl, OCF_3, NO_2, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl, and

each of R^{12} and R^{13} is, independently, H, Cl, Br, OH, OCH_3, OCF_3, NO_2, and NH_2, or R^{12} and R^{13} together form a single bond.

3-4. (Canceled)

5. (Original) The method of claim 2, wherein said compound of formula (I) is acepromazine, chlorfenethazine, chlorpromazine, cyamemazine, fluphenazine, mepazine, methotrimeprazine, methoxypromazine, norchlorpromazine, perazine, perphenazine, prochlorperazine, promethazine, propiomazine, putaperazine, thiethylperazine, thiopropazate, thioridazine, trifluoperazine, or triflupromazine.

6. (Previously presented) The method of claim 2, wherein said compound of formula (II) is 2,5-bis(4-amidinophenyl)furan, 2,5-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, 2,5-bis(4-amidinophenyl)furan-bis-O-4-fluorophenyl, 2,5-bis(4-

amidinophenyl)furan-bis-O-4-methoxyphenyl, 2,4-bis(4-amidinophenyl)furan, 2,4-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, 2,4-bis(4-amidinophenyl)furan-bis-O-4-fluorophenyl, 2,4-bis(4-amidinophenyl)furan-bis-O-4-methoxyphenyl, 2,5-bis(4-amidinophenyl) thiophene, 2,5-bis(4-amidinophenyl) thiophene-bis-O-methylamidoxime, 2,4-bis(4-amidinophenyl)thiophene, or 2,4-bis(4-amidinophenyl)thiophene-bis-O-methylamidoxime.

7. (Previously presented) The method of claim 2, wherein said compound of formula (I) and compound of formula (II) are administered within ten days of each other.

8. (Original) The method of claim 7, wherein said compound of formula (I) and compound of formula (II) are administered within five days of each other.

9. (Original) The method of claim 8, wherein said compound of formula (I) and compound of formula (II) are administered within twenty-four hours of each other.

10. (Currently amended) A method for treating a patient who has lung cancer ~~a neoplasm~~, or inhibiting the development of lung cancer ~~a neoplasm~~ in a patient, said method comprising administering to said patient:

a) a first compound selected from acepromazine, chlorfenethazine, chlorpromazine, cyamemazine, fluphenazine, mepazine, methotrimeprazine,

methoxypromazine, norchlorpromazine, perazine, perphenazine, prochlorperazine, promethazine, propiomazine, putaperazine, thiethylperazine, thiopropazate, thioridazine, trifluoperazine, and triflupromazine, or a pharmaceutically acceptable salt thereof, and

b) a second compound selected from amicarbalide, 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane, 1,3-bis(4'-(N-hydroxyamidino)phenoxy)propane, 1,3-bis(2'-methoxy-4'-(N-hydroxyamidino)phenoxy)propane, 1,4-bis(4'-(N-hydroxyamidino)phenoxy)butane, 1,5-bis(4'-(N-hydroxyamidino)phenoxy)pentane, 1,4-bis(4'-(N-hydroxyamidino)phenoxy)butane, 1,3-bis(4'-(4-hydroxyamidino)phenoxy)propane, 1,3-bis(2'-methoxy-4'-(N-hydroxyamidino)phenoxy)propane, 2,5-bis[4-amidinophenyl]furan, 2,5-bis[4-amidinophenyl]furan-bis-amidoxime, 2,5-bis[4-amidinophenyl]furan-bis-O-methylamidoxime, 2,5-bis[4-amidinophenyl]furan-bis-O-ethylamidoxime, 2,5-bis(4-amidinophenyl)furan-bis-O-4-fluorophenyl, 2,5-bis(4-amidinophenyl)furan-bis-O-4-methoxyphenyl, 2,4-bis(4-amidinophenyl)furan, 2,4-bis(4-amidinophenyl)furan-bis-O-methylamidoxime, 2,4-bis(4-amidinophenyl)furan-bis-O-4-fluorophenyl, 2,4-bis(4-amidinophenyl)furan-bis-O-4-methoxyphenyl, 2,5-bis(4-amidinophenyl) thiophene, 2,5-bis(4-amidinophenyl) thiophene-bis-O-methylamidoxime, 2,4-bis(4-amidinophenyl)thiophene, 2,4-bis(4-amidinophenyl)thiophene-bis-O-methylamidoxime, 2,8-diamidinodibenzothiophene, 2,8-bis(N-isopropylamidino)carbazole, 2,8-bis(N-hydroxyamidino)carbazole, 2,8-bis(2-imidazolinyl)dibenzothiophene, 2,8-bis(2-imidazolinyl)-5,5-dioxodibenzothiophene, 3,7-diamidinodibenzothiophene, 3,7-bis(N-

isopropylamidino)dibenzothiophene, 3,7-bis(N-hydroxyamidino)dibenzothiophene, 3,7-diaminodibenzothiophene, 3,7-dibromodibenzothiophene, 3,7-dicyanodibenzothiophene, 2,8-diamidinodibenzofuran, 2,8-di(2-imidazolinyl)dibenzofuran, 2,8-di(N-isopropylamidino)dibenzofuran, 2,8-di(N-hydroxylamidino)dibenzofuran, 3,7-di(2-imidazolinyl)dibenzofuran, 3,7-di(isopropylamidino)dibenzofuran, 3,7-di(N-hydroxylamidino)dibenzofuran, 2,8-dicyanodibenzofuran, 4,4'-dibromo-2,2'-dinitrobiphenyl, 2-methoxy-2'-nitro-4,4'-dibromobiphenyl, 2-methoxy-2'-amino-4,4'-dibromobiphenyl, 3,7-dibromodibenzofuran, 3,7-dicyanodibenzofuran, 2,5-bis(5-amidino-2-benzimidazolyl)pyrrole, 2,5-bis[5-(2-imidazolinyl)-2-benzimidazolyl]pyrrole, 2,6-bis[5-(2-imidazolinyl)-2-benzimidazolyl]pyridine, 1-methyl-2,5-bis(5-amidino-2-benzimidazolyl)pyrrole, 1-methyl-2,5-bis[5-(2-imidazolyl)-2-benzimidazolyl]pyrrole, 1-methyl-2,5-bis[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyrrole, 2,6-bis(5-amidino-2-benzimidazoyl)pyridine, 2,6-bis[5-(1,4,5,6-tetrahydro-2-pyrimidinyl)-2-benzimidazolyl]pyridine, 2,5-bis(5-amidino-2-benzimidazolyl)furan, 2,5-bis-[5-(2-imidazolinyl)-2-benzimidazolyl]furan, 2,5-bis-(5-N-isopropylamidino-2-benzimidazolyl)furan, 2,5-bis-(4-guanylphenyl)furan, 2,5-bis(4-guanylphenyl)-3,4-dimethylfuran, 2,5-bis{p-[2-(3,4,5,6-tetrahydropyrimidyl)phenyl]}furan, 2,5-bis[4-(2-imidazolinyl)phenyl]furan, 2,5[bis-{4-(2-tetrahydropyrimidinyl)}phenyl]-3-(p-tolyloxy)furan, 2,5[bis{4-(2-imidazolinyl)}phenyl]-3-(p-tolyloxy)furan, 2,5-bis{4-[5-(N-2-aminoethylamido)benzimidazol-2-yl]phenyl}furan, 2,5-bis[4-(3a,4,5,6,7,7a-hexahydro-1H-benzimidazol-2-yl)phenyl]furan, 2,5-bis[4-(4,5,6,7-tetrahydro-1H-1,3-diazepin-2-

yl)phenyl]furan, 2,5-bis(4-N,N-dimethylcarboxhydrazidephenyl)furan, 2,5-bis{4-[2-(N-2-hydroxyethyl)imidazolinyl]phenyl}furan, 2,5-bis[4-(N-isopropylamidino)phenyl]furan, 2,5-bis{4-[3-(dimethylaminopropyl)amidino]phenyl}furan, 2,5-bis{4-[N-(3-aminopropyl)amidino]phenyl}furan, 2,5-bis[2-(imidzaolinyl)phenyl]-3,4-bis(methoxymethyl)furan, 2,5-bis[4-N-(dimethylaminoethyl)guanyl]phenylfuran, 2,5-bis{4-[(N-2-hydroxyethyl)guanyl]phenyl}furan, 2,5-bis[4-N-(cyclopropylguanyl)phenyl]furan, 2,5-bis[4-(N,N-diethylaminopropyl)guanyl]phenylfuran, 2,5-bis{4-[2-(N-ethylimidazolinyl)]phenyl}furan, 2,5-bis{4-[N-(3-pentylguanyl)]}phenylfuran, 2,5-bis[4-(2-imidazolinyl)phenyl]-3-methoxyfuran, 2,5-bis[4-(N-isopropylamidino)phenyl]-3-methylfuran, bis[5-amidino-2-benzimidazolyl]methane, bis[5-(2-imidazolyl)-2-benzimidazolyl]methane, 1,2-bis[5-amidino-2-benzimidazolyl]ethane, 1,2-bis[5-(2-imidazolyl)-2-benzimidazolyl]ethane, 1,3-bis[5-amidino-2-benzimidazolyl]propane, 1,3-bis[5-(2-imidazolyl)-2-benzimidazolyl]propane, 1,4-bis[5-amidino-2-benzimidazolyl]propane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]butane, 1,8-bis[5-amidino-2-benzimidazolyl]octane, trans-1,2-bis[5-amidino-2-benzimidazolyl]ethene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-methylbutane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2-ethylbutane, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1-methyl-1-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-2,3-diethyl-2-butene, 1,4-bis[5-(2-imidazolyl)-2-benzimidazolyl]-1,3-butadiene, 1,4-bis[5-(2-

imidazolyl)-2-benzimidazolyl]-2-methyl-1,3-butadiene, bis[5-(2-pyrimidyl)-2-benzimidazolyl]methane, 1,2-bis[5-(2-pyrimidyl)-2-benzimidazolyl]ethane, 1,3-bis[5-amidino-2-benzimidazolyl]propane, 1,3-bis[5-(2-pyrimidyl)-2-benzimidazolyl]propane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]butane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methylbutane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-ethylbutane, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1-methyl-1-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2,3-diethyl-2-butene, 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-1,3-butadiene, and 1,4-bis[5-(2-pyrimidyl)-2-benzimidazolyl]-2-methyl-1,3-butadiene, 2,4-bis(4-guanylphenyl)pyrimidine, 2,4-bis(4-imidazolin-2-yl)pyrimidine, 2,4-bis[(tetrahydropyrimidinyl-2-yl)phenyl]pyrimidine, 2-(4-[N-i-propylguanyl]phenyl)-4-(2-methoxy-4-[N-i-propylguanyl]phenyl)pyrimidine, 4-(N-cyclopentylamidino)-1,2-phenylene diamine, 2,5-bis-[2-(5-amidino)benzimidazoyl]furan, 2,5-bis[2-{5-(2-imidazolino)}benzimidazoyl]furan, 2,5-bis[2-(5-N-isopropylamidino)benzimidazoyl]furan, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazoyl]furan, 2,5-bis[2-(5-amidino)benzimidazoyl]pyrrole, 2,5-bis[2-{5-(2-imidazolino)}benzimidazoyl]pyrrole, 2,5-bis[2-(5-N-isopropylamidino)benzimidazoyl]pyrrole, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazoyl]pyrrole, 1-methyl-2,5-bis[2-(5-amidino)benzimidazoyl]pyrrole, 2,5-bis[2-{5-(2-imidazolino)}benzimidazoyl]-1-methylpyrrole, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazoyl]-1-methylpyrrole, 2,5-

bis[2-(5-N-isopropylamidino)benzimidazoyl]thiophene, 2,6-bis[2-{5-(2-imidazolino)}benzimidazoyl]pyridine, 2,6-bis[2-(5-amidino)benzimidazoyl]pyridine, 4,4'-bis[2-(5-N-isopropylamidino)benzimidazoyl]-1,2-diphenylethane, 4,4'-bis[2-(5-N-cyclopentylamidino)benzimidazoyl]-2,5-diphenylfuran, 2,5-bis[2-(5-amidino)benzimidazoyl]benzo[b]furan, 2,5-bis[2-(5-N-cyclopentylamidino)benzimidazoyl]benzo[b]furan, 2,7-bis[2-(5-N-isopropylamidino)benzimidazoyl]fluorene, 2,5-bis[4-(3-(N-morpholinopropyl)carbamoyl)phenyl]furan, 2,5-bis[4-(2-N,N-dimethylaminoethylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N,N-dimethylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N-methyl-3-N-phenylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[4-(3-N, N^8,N^{11}-trimethylaminopropylcarbamoyl)phenyl]furan, 2,5-bis[3-amidinophenyl]furan, 2,5-bis[3-(N-isopropylamidino)amidinophenyl]furan, 2,5-bis[3[(N-(2-dimethylaminoethyl)amidino]phenylfuran, 2,5-bis[4-(N-2,2,2-trichloroethoxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-thioethylcarbonyl) amidinophenyl]furan, 2,5-bis[4-(N-benzyloxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-phenoxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-(4-fluoro)-phenoxycarbonyl)amidinophenyl]furan, 2,5-bis[4-(N-(4-methoxy)phenoxycarbonyl)amidinophenyl]furan, 2,5-bis[4(1-acetoxyethoxycarbonyl)amidinophenyl]furan, and 2,5-bis[4-(N-(3-fluoro)phenoxycarbonyl)amidinophenyl]furan, or a pharmaceutically acceptable salt

thereof, wherein said first compound and said second compound are administered simultaneously or within 14 days of each other, in amounts sufficient to treat or inhibit the development of lung cancer ~~a neoplasm~~ in said patient.

11. (Canceled)

12. (Currently amended) The method of claim 10 ~~11~~, wherein said method is performed in conjunction with administering to said patient an additional treatment for cancer, said additional treatment comprising surgery, radiation therapy, chemotherapy, immunotherapy, anti-angiogenesis therapy, or gene therapy, wherein said method and said additional treatment are administered within 6 months of each other.

13. (Previously presented) The method of claim 12, wherein said additional treatment and said method of claim 10 are administered within fourteen days of each other.

14. (Previously presented) The method of claim 12, wherein said additional treatment and said method of claim 10 are administered within five days of each other.

15. (Previously presented) The method of claim 12, wherein said additional treatment and said method of claim 10 are administered within twenty-four hours of each other.

16-20. (Canceled)

21. (Currently amended) The method of claim 10 ~~20~~, wherein said lung cancer is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

22-25. (Canceled)

26. (Currently amended) The method of claim 10, wherein said first compound ~~of formula (I)~~ and said second compound ~~of formula (II)~~ are administered to said patient by intravenous, intramuscular, inhalation, rectal, or oral administration.

27. (Canceled)

28. (Currently amended) A method for treating a patient who has lung cancer ~~a neoplasm~~, or inhibiting the development of lung cancer ~~a neoplasm~~ in a patient, said method comprising administering to said patient a composition comprising:

a) a first compound having the formula (I):



(I) ,

or a pharmaceutically acceptable salt thereof,

wherein R^2 is selected from the group consisting of: CF_3, halo, OCH_3, $COCH_3$, CN, OCF_3, $COCH_2CH_3$, $CO(CH_2)_2CH_3$, and SCH_2CH_3;

R^9 has the formula:



,

wherein n is 0 or 1, each of R^{32}, R^{33}, and R^{34} is, independently, H or substituted or unsubstituted C_{1-6} alkyl, and Z is $NR^{35}R^{36}$ or OR^{37}, wherein each of R^{35} and R^{36} is, independently, H, substituted or unsubstituted C_{1-6} alkyl, substituted or unsubstituted alkaryl, substituted or unsubstituted alkheteroaryl, and R^{37} is H, C_{1-6} alkyl, or C_{1-7} acyl, wherein any of R^{33}, R^{34}, R^{35}, and R^{36} can be optionally taken together with the intervening carbon atoms to form one or more five- to seven-membered rings that may optionally contain non-vicinal O, S, or N, and are substituted with one or more hydrogens, substituted or unsubstituted C_{1-6} alkyl groups, C_{6-12} aryl groups, alkoxy

groups, halogen groups, substituted or unsubstituted alkaryl groups, or substituted or unsubstituted alkheteroaryl groups;

each of R^1, R^3, R^4, R^5, R^6, R^7, and R^8 is independently H, OH, F, OCF_3, or OCH_3; and W is selected from the group consisting of:



, and ; and

b) a second compound of formula (II):



(II),

wherein A is



,

each of X and Y is, independently, O or NH,

p is an integer between 2 and 6, inclusive,

each of m and n is, independently, an integer between 0 and 2, inclusive, wherein the sum of m and n is greater than 0,

each of R^{10} and R^{11} is, independently, selected from the group represented by



,

wherein R^{21} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or , R^{22} is H, C_1-

C_6 alkyl, C_1-C_8 cycloalkyl, C_6-C_{18} aryloxy C_1-C_6 alkyl, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, carbo(C_1-C_6 alkoxy), carbo(C_6-C_{18} aryl-C_1-C_6 alkoxy), carbo(C_6-C_{18} aryloxy), or C_6-C_{18} aryl, and R^{20} is H, OH, or oxy(C_1-C_6 alkyl), or R^{20} and R^{21} together represent



wherein each of R^{23}, R^{24}, and R^{25} is, independently, H, C_1-C_6 alkyl, halogen, or trifluoromethyl, each of R^{26}, R^{27}, R^{28}, and R^{29} are, independently, H or C_1-C_6 alkyl, and R^{30} is H, halogen, trifluoromethyl, OCF_3, NO_2, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl,

each of R^{12} and R^{13} is, independently, H, Cl, Br, OH, OCH_3, OCF_3, NO_2, and NH_2, or R^{12} and R^{13} together form a single bond;

or A is



each of X and Y is, independently, O or NH,

p is an integer between 2 and 6, inclusive,

each of m and n is 0, and

each of R^{10} and R^{11} is, independently, selected from the group represented by



wherein R^{21} is C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl, R^{22} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, carbo(C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryl C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryloxy), or C_6-C_{18} aryl, and R^{20} is H, OH, or C_1-C_6 alkyloxy, or R^{20} and R^{21} together represent



wherein each of R^{23}, R^{24}, and R^{25} is, independently, H, C_1-C_6 alkyl, halogen, or trifluoromethyl, each of R^{26}, R^{27}, and R^{28} is, independently, H or C_1-C_6 alkyl, and R^{29} is C_1-C_6 alkyl, C_1-C_6 alkyloxy, or trifluoromethyl;

or A is



each of X and Y is, independently, O, NR^{19}, or S,

each of R^{14} and R^{19} is, independently, H or C_1-C_6 alkyl,

each of R^{15}, R^{16}, R^{17}, and R^{18} is, independently, H, C_1-C_6 alkyl, halogen, C_1-C_6 alkyloxy, C_6-C_{18} aryloxy, or C_6-C_{18} aryl C_1-C_6 alkyloxy,

R^{31} is C_1-C_6 alkyl,

p is an integer between 2 and 6, inclusive,

each of m and n is, independently, an integer between 0 and 2, inclusive,

each of R^{10} and R^{11} is, independently, selected from the group represented by



,

wherein R^{21} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkoxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl, R^{22} is H, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_6-C_{18} aryloxy C_1-C_6 alkyl, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, carbo(C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryl C_1-C_6 alkyloxy), carbo(C_6-C_{18} aryloxy), or C_6-C_{18} aryl, and R^{20} is H, OH, or C_1-C_6 alkyloxy, or R^{20} and R^{21} together represent



wherein each of R^{23}, R^{24}, and R^{25} is, independently, H, C_1-C_6 alkyl, halogen, or trifluoromethyl, each of R^{26}, R^{27}, R^{28}, and R^{29} are, independently, H or C_1-C_6 alkyl, and R^{30} is H, halogen, trifluoromethyl, OCF_3, NO_2, C_1-C_6 alkyl, C_1-C_8 cycloalkyl, C_1-C_6 alkyloxy, C_1-C_6 alkyloxy C_1-C_6 alkyl, hydroxy C_1-C_6 alkyl, C_1-C_6 alkylamino C_1-C_6 alkyl, amino C_1-C_6 alkyl, or C_6-C_{18} aryl, and

each of R^{12} and R^{13} is, independently, H, Cl, Br, OH, OCH_3, OCF_3, NO_2, and NH_2, or R^{12} and R^{13} together form a single bond.

29. (Previously presented) The method of claim 28, wherein said composition is administered to said patient by intravenous, intramuscular, inhalation, rectal, or oral administration.

30-40. (Canceled)

41. (Currently amended) The method of claim 28 ~~40~~, wherein said method is performed in conjunction with administering to said patient an additional treatment for cancer, said additional treatment comprising surgery, radiation therapy, chemotherapy, immunotherapy, anti-angiogenesis therapy, or gene therapy, wherein said method and said additional treatment are administered within 6 months of each other.

42. (Previously presented) The method of claim 41, wherein said additional treatment and said method of claim 28 are administered within fourteen days of each other.

43. (Previously presented) The method of claim 42, wherein said additional treatment and said method of claim 28 are administered within five days of each other.

44. (Previously presented) The method of claim 43, wherein said additional treatment and said method of claim 28 are administered within twenty-four hours of each other.

45-48. (Canceled)

49. (Currently amended) The method of claim 28 ~~48~~, wherein said lung cancer is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

50-53. (Canceled)

54. (Previously presented) The method of claim 2, wherein said compound of formula (I) and compound of formula (II) are administered to said patient by intravenous, intramuscular, inhalation, rectal, or oral administration.

55-57. (Canceled)

58. (Currently amended) The method of claim 2 ~~57~~, wherein said lung cancer is selected from the group consisting of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.

59-62. (Canceled)